1.44 USD
↗ 0.02 (1.41%)AT CLOSE (11:59 AM EDT)
Geron Corp
GERNNASDAQ • USD
1.44
↘ 0.00 (0.07%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
1.44
↘ 0.00 (0.07%)
Market: CLOSED
Geron Corp (GERN) trades at $1.44 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place GERN at a fair price relative to peers.
Technical & fundamental data as of Jul 17, 2026.
Open?$1.41
High?$1.49
Low?$1.40
Prev. Close?$1.42
Volume?4.8M
Avg. Volume?13.4M
VWAP?$1.45
Rel. Volume?0.36x
Bid / Ask
Bid?$1.22 × 100
Ask?$1.65 × 100
Spread?$0.43
Midpoint?$1.44
Valuation & Ratios
Market Cap?911.0M
Shares Out?641.5M
Float?625.8M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?3.98
EPS?-$0.10
Dividend?0.00%
Ex-Dividend?N/A
RelatedALKS
News
Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Themes
Address
919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
Phone: (650) 473-7700
FOSTER CITY, CA 94404
Phone: (650) 473-7700
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?62
Short Sent.?35
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.08Distress
Confidence?58%Low
Short InterestHigh
Short % of Float?12.82%High
Short Interest?80.2M
Days to Cover?4.7
Free Float625.8M
Avg Daily Volume17.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?6.75Strong
Quick Ratio?4.94Strong
Cash Ratio?0.94Adequate
Debt/Equity?1.09Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score75/100
P/E?N/A▾
P/B?3.98FAIR▾
Peers100
S&P45
P/S?4.65FAIR▾
Peers100
S&P32
P/FCF?N/A▾
EV/EBITDA?-31.5CHEAP▾
Peers100
S&P97
EV/Sales?5.57FAIR▾
Peers100
S&P31
Returns & Efficiency
ROE?-29.4%WEAK▾
Peers50
S&P6
ROA?-12.6%WEAK▾
Peers50
S&P3
Cash Flow & Enterprise
FCF?$-126297000
Enterprise Value?$1.1B
Fundamentals ratios updated end of day